Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. |
|
|
|
|
|
|
Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. |
|
|
|
|
|
|